The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
Laboratory Corporation of America Holdings added a new risk factor in 2025 addressing AI and machine learning tools used in its operations and by third parties, reflecting heightened concern about emerging technology risks. The company substantively modified 11 existing risk factors, with notable changes to disclosures covering acquisition strategy, third-party cybersecurity vulnerabilities, and data security threats, indicating a material refinement of previously disclosed risks rather than introduction of entirely new categories.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟢 New in Current Filing
The use of AI and machine learning tools in our operations and the services of our third-parties may introduce risks that could adversely affect our business, financial condition, and reputation.
🔒
🟡 Modified
A failure to identify suitable acquisition targets and successfully close and integrate acquisitions could have a material adverse effect on the Company’s business objectives and its revenues and profitability.
🔒
🟡 Modified
Any cybersecurity incidents affecting the information technology systems of third parties that provide services to the Company could have a material adverse effect on the Company's operations.
🔒
🟡 Modified
Cybersecurity incidents and unauthorized access to the Company's or its customers’ data could harm the Company’s reputation and adversely affect its business.
🔒
🟡 Modified
Operations may be disrupted and adversely impacted by events beyond the Company’s control, including natural disasters, adverse weather, geopolitical events, public health crises, acts of terrorism, disruption to supply chain, and inaccessibility of natural resources.
🔒
🟡 Modified
Discontinuation or recalls of products used in the performance of testing, failure to develop or acquire licenses for new or improved testing technologies, or the Company’s customers using new technologies to replace offerings currently provided by the Company could adversely affect its business.
🔒
🟡 Modified
The spin-off of Fortrea may not achieve the intended results.
🔒
🟡 Modified
U.S. Food and Drug Administration (FDA) regulation of laboratory-developed tests (LDTs) and regulation by other countries of diagnostic offerings could have a material adverse effect upon the Company’s business.
🔒
🟡 Modified
General or macro-economic factors and significant fluctuations in economic conditions in the U.S. and globally may have a material adverse effect upon the Company.
🔒
🟡 Modified
Continued changes in healthcare reimbursement models and products (e.g., health insurance exchanges), changes in government payment and reimbursement systems, or changes in payer mix, including an increase in third-party benefits management and value-based payment models, could have a material adverse effect on the Company’s revenues, profitability and cash flow.
🔒
🟡 Modified
Increased competition, including price competition, could have an adverse effect on the Company’s revenues and profitability.
🔒
🟡 Modified
Views on matters relating to corporate responsibility and governance and the perception of the Company’s activities in these areas by stakeholders may impact the Company’s business and reputation.
🔒